

Special Issue

Vaccine-Induced Anti-tumor Immunity

Message from the Guest Editors

Cancer is one of the leading causes of death worldwide and represents a significant public health challenge. Currently, with the success of immune checkpoint inhibition treatment, research on tumor vaccines, which are an important component of tumor immunotherapy. In order to better understand and keep up with the latest scientific advancements and development trends in the field of tumor vaccine research, this Special Issue is focused on the recent scientific and technical progress made in this field. Based on your extensive knowledge and experience, we are pleased to invite you to contribute with original research articles and reviews about cancer vaccines. Research areas may include (but are not limited to) the following:

- The design and development and anti-tumor prophylactic and therapeutic effects of tumor vaccine.
- The mechanisms of the vaccine-induced anti-tumor immune response.
- The modulation of the tumor immune microenvironment using tumor vaccines
- Combination therapy of tumor vaccines with other therapies.
- Recent advances in novel tumor prophylactic and therapeutic vaccines.

Guest Editors

Prof. Dr. Haihong Zhang

College of Life Sciences, Jilin University, Changchun, China

Prof. Dr. Xianghui Yu

School of Life Science, Jilin University, Changchun, China

Prof. Dr. Yongge Wu

National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun 130012, China

Deadline for manuscript submissions

closed (30 June 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/187656

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).